Literature DB >> 31264739

Overexpression of heme oxygenase-1 in microenvironment mediates vincristine resistance of B-cell acute lymphoblastic leukemia by promoting vascular endothelial growth factor secretion.

Kunlin Yu1,2, Jishi Wang2, Tingting Lu2, Dan Ma2, Danna Wei1,2, Yongling Guo1,2, Bingqin Cheng1,2, Weili Wang1,2, Qin Fang3.   

Abstract

Chemoresistance often causes treatment failure of B-cell acute lymphoblastic leukemia (B-ALL). However, the mechanism remains unclear at present. Herein, overexpression of heme oxygenase-1 (HO-1) was found in the bone marrow stromal cells (BMSCs) from B-ALL patients developing resistance to vincristine (VCR), a chemotherapeutic agent. Two B-ALL cell lines Super B15 and CCRF-SB were cocultured with BMSCs transfected with lentivirus to regulate the expression of HO-1. Silencing HO-1 expression in BMSCs increased the apoptotic rates of B-ALL cell lines induced by VCR, whereas upregulating HO-1 expression reduced the rate. Cell cycle can be arrested in the G2/M phase by VCR. In contrast, B-ALL cells were arrested in the G0/G1 phase due to HO-1 overexpression in BMSCs, which avoided damage from the G2/M phase. Vascular endothelial growth factor (VEGF) in BMSCs, as a key factor in the microenvironment-associated chemoresistance, was also positively coexpressed with HO-1. VEGF secretion was markedly increased in BMSCs with HO-1 upregulation but decreased in BMSCs with HO-1 silencing. B-ALL cell lines became resistant to VCR when cultured with VEGF recombinant protein, so VEGF secretion induced by HO-1 expression may promote the VCR resistance of B-ALL cells. As to the molecular mechanism, the PI3K/AKT pathway mediated regulation of VEGF by HO-1. In conclusion, this study clarifies a mechanism by which B-ALL is induced to resist VCR through HO-1 overexpression in BMSCs, and provides a novel strategy for overcoming VCR resistance in clinical practice.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  B-cell acute lymphoblastic leukemia; bone marrow stromal cell; drug resistance; heme oxygenase-1; vascular endothelial growth factor; vincristine

Year:  2019        PMID: 31264739     DOI: 10.1002/jcb.29046

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

Review 1.  The Bone Marrow Microenvironment in B-Cell Development and Malignancy.

Authors:  Anastasia M Hughes; Vincent Kuek; Rishi S Kotecha; Laurence C Cheung
Journal:  Cancers (Basel)       Date:  2022-04-22       Impact factor: 6.575

Review 2.  Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia.

Authors:  Agata Pastorczak; Krzysztof Domka; Klaudyna Fidyt; Martyna Poprzeczko; Malgorzata Firczuk
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

Review 3.  Abnormal bone marrow microenvironment: the "harbor" of acute lymphoblastic leukemia cells.

Authors:  Zehui Chen; Yaxin Zheng; Yaling Yang; Junnan Kang; M James You; Chen Tian
Journal:  Blood Sci       Date:  2021-04-28

4.  Transcriptome Analysis Identifies LINC00152 as a Biomarker of Early Relapse and Mortality in Acute Lymphoblastic Leukemia.

Authors:  Diego Alberto Bárcenas-López; Juan Carlos Núñez-Enríquez; Alfredo Hidalgo-Miranda; Fredy Omar Beltrán-Anaya; Didier Ismael May-Hau; Elva Jiménez-Hernández; Vilma Carolina Bekker-Méndez; Janet Flores-Lujano; Aurora Medina-Sansón; Edna Liliana Tamez-Gómez; Víctor Hugo López-García; José Ramón Lara-Ramos; Nora Nancy Núñez-Villegas; José Gabriel Peñaloza-González; Luz Victoria Flores-Villegas; Raquel Amador-Sánchez; Rosa Martha Espinosa-Elizondo; Jorge Alfonso Martín-Trejo; Martha Margarita Velázquez-Aviña; Laura Elizabeth Merino-Pasaye; María Luisa Pérez-Saldívar; David Aldebarán Duarte-Rodríguez; José Refugio Torres-Nava; Beatriz Cortés-Herrera; Karina Anastacia Solís-Labastida; Ana Itamar González-Ávila; Jessica Denisse Santillán-Juárez; Alejandra Jimena García-Velázquez; Haydee Rosas-Vargas; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; Juan Manuel Mejía-Aranguré; Silvia Jiménez-Morales
Journal:  Genes (Basel)       Date:  2020-03-13       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.